Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

nd strong inhibitors or inducers of CYP3A4 should be avoided as they may affect serum concentration of Tasigna.

Concomitant strong CYP3A4 inhibitors

The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs (including, but not limited to amiodarone, disopyramide, procainamide, quinidine, and sotalol) and other drugs that may prolong QT interval (including, but not limited to chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil, and pimozide) should be avoided. Should treatment with any of these agents be required, it is recommended that therapy with Tasigna be interrupted. If interruption of treatment with Tasigna is not possible, patients who require treatment with a drug that prolongs QT or strongly inhibits CYP3A4 should be closely monitored for prolongation of the QT interval, and a dose reduction to 1/2 the daily dose is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be allowed before Tasigna is adjusted upward to the indicated dose. Close monitoring for prolongation of the QT interval is indicated for patients who cannot avoid strong CYP3A4 inhibitors. Grapefruit products and other foods that are known to inhibit CYP3A4 should also be avoided.

Concomitant strong CYP3A4 inducers

The concomitant use of strong CYP3A4 inducers should be avoided (including, but not limited to, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital). Patients should also refrain from taking St John's Wort. If patients must be co-administered a strong CYP3A4 inducer, the dose of Tasigna may need to be increased, depending on patient tolerability. If the strong inducer is discontinued, the Tasigna dose should be reduced to the indicated Tasigna dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. In vitro studies also suggest that nilotinib may i
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... (PRWEB) , ... August 28, ... ... Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on ... alignment demonstration approved for a December 2015 launch; and Idaho’s partnership to ...
(Date:8/28/2015)... AB (PRWEB) , ... August 28, 2015 , ... External ... The Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with ... Heart Fit Clinic has been in business since 2007 helping people prevent and ...
(Date:8/28/2015)... ... 2015 , ... A complimentary webinar offered by healthcare consulting and accounting firm ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement Program ... Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September 2, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Inc. ’s online medical consultations result in high percentages of change to treatment ... the Center for Healthcare Informatics at Tennessee Tech University and analyzed WorldCare’s second ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... Scientists presented new research today demonstrating the impact ... studies examine how such environmental information can be transmitted ... known as epigenetics. This new knowledge could ultimately improve ... and how a parent,s exposure to drugs, alcohol, and ...
... common among cardiac arrest survivors. The survival and ... patients with preexisting cardiomyopathy, compared with those patients ... presented Nov. 14 at the at the American ... Therefore, the researchers recommended the use of therapeutic ...
... research linking alcohol to breast cancer risk, a new study ... that adolescent girls with a family history of breast disease ... cancer have a higher risk of developing benign breast ... without a family history, this already-elevated risk rises with increasing ...
... non-small cell lung cancer who have mutations in the KRAS ... according to results of a recent study conducted by Quintiles ... "Our findings indicate that when patients with lung cancer have ... to antifolate drugs," said lead researcher Sarah Bacus, Ph.D., Quintiles ...
... team of researchers co-led by the University of Pennsylvania ... capable of recording brain activity from the cortical surface ... make possible a whole new generation of brain-computer interfaces ... work was published in Nature Neuroscience. ...
... in people with dangerous heart arrhythmias, according to research ... , Wearable cardioverter defibrillators are used by people who ... including those with weakened heart function, awaiting cardiac transplant ... from receiving an implanted defibrillator. , The device ...
Cached Medicine News:Health News:Nature and nurture work together to shape the brain 2Health News:Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy 2Health News:Girls with family history of breast disease should avoid alcohol 2Health News:Girls with family history of breast disease should avoid alcohol 3Health News:Antifolates show promise against NSCLC subtype 2Health News:A more flexible window into the brain 2Health News:A more flexible window into the brain 3Health News:Wearable defibrillator can prevent death in people with arrhythmias 2
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
Inquire...
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... false signals and contamination caused by ... Barrier Tips offer performance and economy ... (PCR(a)), radioactive isotopes, tissue culture fluids, ... , ,Promega Barrier Tips are made ...
Medicine Products: